Trial Profile
Prevention of atherosclerosis by SGLT2 inhibitor; multicenter, randomized controlled study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms PROTECT
- 01 Jan 2024 Results of sub-analysis assessing if ipragliflozin delays carotid atherosclerosis in patients with type 2 diabetes published in the Hypertension Research
- 01 Aug 2022 Planned End Date changed from 31 Oct 2020 to 24 Dec 2020.
- 15 Jun 2018 Status changed from recruiting to active, no longer recruiting.